# Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

> **NCT02116777** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Childhood Solid Neoplasm
- Recurrent Childhood Central Nervous System Neoplasm
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Malignant Solid Neoplasm
- Refractory Central Nervous System Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Talazoparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02116777
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-16
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116777, "Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02116777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*